Why the study?
Is the P2Y1 receptor mutated or dysfunctional in a patient with severe deficiency of ADP-induced platelet aggregation?
Is the P2Y1 receptor mutated or dysfunctional in a patient with severe deficiency of ADP-induced platelet aggregation?
The findings suggest that a third P2 receptor coupled to adenylyl cyclase is involved in ADP-induced platelet aggregation, as P2Y1 and P2X1 were normal in a patient with aggregation deficiency.
P2Y1 variants unlikely to explain this patient's aggregation defect; hypothesis-generating for a third ADP receptor in platelet disorders.
ADP is a key stimulus inducing platelet shape change and aggregation, a rise in internal calcium and inhibition of adenylyl cyclase. These signaling pathways are thought to be activated by three independent receptors, but to date only the P2Y1 receptor responsible for calcium mobilization and the ionotropic P2X1 receptor have been identified. We report here the characteristics of the P2Y1 receptor in a patient presenting a selective deficiency of ADP-induced aggregation. Cloning of the P2Y1 gene revealed that the patient's DNA and mRNA were normal. Pharmacological studies showed that the P2Y1 receptor was expressed and functional in patient's platelets. Hence, the P2Y, receptor is not the cause of the impaired ADP-induced platelet aggregation in this patient. The P2X1 mRNA was also found to be present and normal. These findings add evidence to previous observations suggesting that a third P2 receptor coupled to adenylyl cyclase may be involved in ADP-induced platelet aggregation.
No takes yet. Share an insight, caveat, or question.
Catherine Léon (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: